Furthermore, Lefort et al. [43] showed the potential benefit in reducing tumor growth and metastasis, especially in trastuzumab-sensitive and trastuzumab-resistant HER2 breast cancers, by targeting the CXCR4/CXCL12 axis. Here, CXCL12 is linked to neoplasm.